Sorry, this entry is only available in German!
Boehringer Ingelheim investiert 11 Milliarden Euro über fünf Jahre in die Entwicklung innovativer Arzneimittel
The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.
As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.